Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Inspra 25mg tablets
0202030X0BBAAAA
|
Inspra | Eplerenone | Cardiovascular System | 1,207 |
|
Depixol 20mg/1ml solution for injection ampoules
0402020G0BBAAAA
|
Depixol (Parenteral) | Flupentixol decanoate | Central Nervous System | 1,206 |
|
Disopyramide 250mg modified-release tablets
0203020G0AAACAC
|
Disopyramide phosphate | Disopyramide phosphate | Cardiovascular System | 1,206 |
|
Hypromellose 0.32% eye drops
1108010F0AABNBN
|
Hypromellose | Hypromellose | Eye | 1,206 |
|
Oxycodone 5mg / Naloxone 2.5mg modified-release tablets
0407020AFAAACAC
|
Oxycodone hydrochloride/naloxone hydrochloride | Oxycodone hydrochloride/naloxone hydrochloride | Central Nervous System | 1,206 |
|
OxyContin 40mg modified-release tablets
0407020ADBCACAH
|
OxyContin | Oxycodone hydrochloride | Central Nervous System | 1,206 |
|
Phytomenadione 10mg tablets
0906060Q0AAACAC
|
Phytomenadione | Phytomenadione | Nutrition and Blood | 1,206 |
|
DHC Continus 120mg tablets
0407020G0BBACAF
|
DHC Continus | Dihydrocodeine tartrate | Central Nervous System | 1,205 |
|
Alimemazine 30mg/5ml oral solution
0304010Y0AAACAC
|
Alimemazine tartrate | Alimemazine tartrate | Respiratory System | 1,204 |
|
Nicorette QuickMist 1mg/dose mouthspray cool berry
0410020B0BBBEBW
|
Nicorette | Nicotine | Central Nervous System | 1,204 |
|
Nyzamac SR 60mg capsules
0206010K0CUABAQ
|
Nyzamac SR | Isosorbide mononitrate | Cardiovascular System | 1,204 |
|
Mepilex XT dressing 11cm x 20cm
20030900063
|
Mepilex XT dressing 11cm x 20cm | Wound Management & Other Dressings | Dressings | 1,202 |
|
ActivHeal Non-Adhesive Foam polyurethane dressing 10cm x 10cm square
20030600330
|
ActivHeal Non-Adhesive Foam polyurethane dressing 10cm x 10cm square | Wound Management & Other Dressings | Dressings | 1,201 |
|
Delmosart 18mg modified-release tablets
0404000M0BJAAAM
|
Delmosart | Methylphenidate hydrochloride | Central Nervous System | 1,201 |
|
Lumecare Advance Carmellose 0.5% eye drops
21300000161
|
Lumecare Advance Carmellose 0.5% eye drops | Eye Products | Appliances | 1,200 |
|
Zirtek Allergy 10mg tablets
0304010I0BBACAA
|
Zirtek | Cetirizine hydrochloride | Respiratory System | 1,200 |
|
Bazuka Extra Strength 26% gel
1307000M0BXABBM
|
Bazuka | Salicylic acid | Skin | 1,199 |
|
PreserVision Lutein capsules
091000000BBVGBT
|
Proprietary compound preparation BNF 0910000 | Other compound vitamin/mineral formulation preparations | Nutrition and Blood | 1,198 |
|
Hydrocortisone 2.5% ointment
1304000V0AABDBD
|
Hydrocortisone (Topical) | Hydrocortisone | Skin | 1,197 |
|
ProSource Plus liquid 30ml sachets citrus berry
0913141C0BBAEAA
|
ProSource RtS 3.3 kcal/ml energy and higher protein liquid | RtS 3.3 kcal/ml energy and higher protein liquid (0913141) | Nutrition and Blood | 1,195 |
|
Biatain Silicone dressing 10cm x 20cm
20030900349
|
Biatain Silicone dressing 10cm x 20cm | Wound Management & Other Dressings | Dressings | 1,194 |
|
Reltebon 10mg modified-release tablets
0407020ADBKABAF
|
Reltebon | Oxycodone hydrochloride | Central Nervous System | 1,191 |
|
Tegaderm + Pad dressing 9cm x 10cm
20030100381
|
Tegaderm + Pad dressing 9cm x 10cm | Wound Management & Other Dressings | Dressings | 1,191 |
|
Vera-Til SR 240mg tablets (Accord Healthcare Ltd)
0206020T0BMACAH
|
Vera-Til | Verapamil hydrochloride | Cardiovascular System | 1,190 |
|
Vicryl Rapide suture 2gauge 75cm length with 19mm curved reverse cutting P needle
20110000448
|
Vicryl Rapide suture 2gauge 75cm length with 19mm curved reverse cutting P needle | Surgical Sutures | Dressings | 1,190 |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.